Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prevnar 13 Advisory Committee Review Moved Back To November

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.

You may also be interested in...



Prevnar 13 In Older Adults Appears To Have Smooth Path To FDA Approval

Advisory committee to give recommendations on the Pfizer vaccine’s safety and immunogenicity using accelerated approval, but no votes mentioned.

Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP

Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.

Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP

Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.

Related Content

Topics

UsernamePublicRestriction

Register

PS072851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel